RX- Antipsychotic Medication Use In Medicaid-Insured Children Decreased Substantially Between 2008 And 2016

MM Curator summary

The article below has been highlighted and summarized by our research team. It is provided here for member convenience as part of our Curator service.


[MM Curator Summary]: Celebrating that now only 55% of Medicaid kids getting a powerful antipsychotic med are missing a relevant diagnosis to validate they need it or suggest are getting their care managed.



Clipped from: https://www.healthaffairs.org/doi/full/10.1377/hlthaff.2022.01625


After the rapid growth of pediatric antipsychotic prescribing in the early 2000s, especially in the Medicaid population, concerns regarding the safety and appropriateness of such prescribing increased. Many states implemented policy and educational initiatives aimed at safer and more judicious antipsychotic use. Antipsychotic use leveled off in the late 2000s, but there have been no recent national estimates of trends in antipsychotic use in children enrolled in Medicaid, and it is unclear how use varied by race and ethnicity. This study observed a sizable decline in antipsychotic use among children ages 2–17 between 2008 and 2016. Although the magnitude of change varied, declines were observed across foster care status, age, sex, and racial and ethnic groups studied. The proportion of children with an antipsychotic prescription who received any diagnosis associated with a pediatric indication that was approved by the Food and Drug Administration increased from 38 percent in 2008 to 45 percent in 2016, which may indicate a trend toward more judicious prescribing.





  • 1 Centers for Medicare and Medicaid Services Medicaid Integrity Group. Atypical antipsychotic medications: use in pediatric patients [Internet]. Baltimore (MD): CMS; 2015 Oct [cited 2023 Apr 27]. Available from: https://www.cms.gov/medicare-medicaid-coordination/fraud-prevention/medicaid-integrity-education/pharmacy-education-materials/downloads/atyp-antipsych-pediatric-factsheet11-14.pdf
    Google Scholar

  • 2 Galling B, Roldán A, Nielsen RE, Nielsen J, Gerhard T, Carbon Met al. Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis. JAMA Psychiatry. 2016;73(3):247–59. Crossref, MedlineGoogle Scholar
  • 3 Ray WA, Stein CM, Murray KT, Fuchs DC, Patrick SW, Daugherty Jet al. Association of antipsychotic treatment with risk of unexpected death among children and youths. JAMA Psychiatry. 2019;76(2):162–71. Crossref, MedlineGoogle Scholar
  • 4 Libowitz MR, Nurmi EL. The burden of antipsychotic-induced weight gain and metabolic syndrome in children. Front Psychiatry. 2021;12:623681. Crossref, MedlineGoogle Scholar
  • 5 Jensen KG, Correll CU, Rudå D, Klauber DG, Decara MS, Fagerlund Bet al. Cardiometabolic adverse effects and its predictors in children and adolescents with first-episode psychosis during treatment with quetiapine-extended release versus aripiprazole: 12-week results from the Tolerance and Effect of Antipsychotics in Children and Adolescents with Psychosis (TEA) Trial. J Am Acad Child Adolesc Psychiatry. 2019;58(11):1062–78. Crossref, MedlineGoogle Scholar
  • 6 Crystal S, Mackie T, Fenton MC, Amin S, Neese-Todd S, Olfson Met al. Rapid growth of antipsychotic prescriptions for children who are publicly insured has ceased, but concerns remain. Health Aff (Millwood). 2016;35(6):974–82. Go to the articleGoogle Scholar
  • 7 Patten SB, Waheed W, Bresee L. A review of pharmacoepidemiologic studies of antipsychotic use in children and adolescents. Can J Psychiatry. 2012;57(12):717–21. Crossref, MedlineGoogle Scholar
  • 8 Crystal S, Olfson M, Huang C, Pincus H, Gerhard T. Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Aff (Millwood). 2009;28(5):w770–81. Go to the articleGoogle Scholar
  • 9 Mackie TI, Hyde J, Palinkas LA, Niemi E, Leslie LK. Fostering psychotropic medication oversight for children in foster care: a national examination of states’ monitoring mechanisms. Adm Policy Ment Health. 2017;44(2):243–57. Crossref, MedlineGoogle Scholar
  • 10 Spence O, Reeves G, dosReis S. Spillover effects of state Medicaid antipsychotic prior authorization policies in US commercially insured youth. Pharmacoepidemiol Drug Saf. 2020;29(9):1064–71. Crossref, MedlineGoogle Scholar
  • 11 Bushnell GA, Crystal S, Olfson M. Trends in antipsychotic medication use in young privately insured children. J Am Acad Child Adolesc Psychiatry. 2021;60(7):877–86. Crossref, MedlineGoogle Scholar
  • 12 Edelsohn GA, Karpov I, Parthasarathy M, Hutchison SL, Castelnovo K, Ghuman Jet al. Trends in antipsychotic prescribing in Medicaid-eligible youth. J Am Acad Child Adolesc Psychiatry. 2017;56(1):59–66. Crossref, MedlineGoogle Scholar
  • 13 Nunes JC, Naccarato T, Stafford RS. Antipsychotics in the California foster care system: a 10-year analysis. J Child Adolesc Psychopharmacol. 2022;32(7):400–7. Crossref, MedlineGoogle Scholar
  • 14 Cataife G, Weinberg DA. Racial and ethnic differences in antipsychotic medication use among children enrolled in Medicaid. Psychiatr Serv. 2015;66(9):946–51. Crossref, MedlineGoogle Scholar
  • 15 To access the appendix, click on the Details tab of the article online.
  • 16 Centers for Medicare and Medicaid Services. DQ Atlas [Internet]. Baltimore (MD): CMS; [cited 2023 Apr 27]. Available from: https://www.medicaid.gov/dq-atlas/welcome
    Google Scholar

  • 17 Nguyen JK, Sanghavi P. A national assessment of legacy versus new generation Medicaid data. Health Serv Res. 2022;57(4):944–56. Crossref, MedlineGoogle Scholar
  • 18 Schmid I, Burcu M, Zito JM. Medicaid prior authorization policies for pediatric use of antipsychotic medications. JAMA. 2015;313(9):966–8. Crossref, MedlineGoogle Scholar
  • 19 Zito JM, Burcu M, McKean S, Warnock R, Kelman J. Pediatric use of antipsychotic medications before and after Medicaid peer review implementation. JAMA Psychiatry. 2018;75(1):100–3. Crossref, MedlineGoogle Scholar
  • 20 Foti ME, Harper G, Moon R, Oestreich G, Snow R, Thompson Jet al. Antipsychotic medication use in Medicaid children and adolescents: report and resource guide from a 16-state study [Internet]. New Brunswick (NJ): Rutgers Center for Education and Research on Mental Health Therapeutics; 2010 Jun [cited 2023 Apr 27]. Available from: https://ifh.rutgers.edu/wp-content/uploads/2019/09/MMDLN-Rutgers-AP_MED_USE_IN_CHILDREN…en_Report_and_Resource_Guide_Final.pdf
    Google Scholar

  • 21 National Committee for Quality Assurance. HEDIS measures for the safe & judicious use of antipsychotic medications in children and adolescents [Internet]. Washington (DC): NCQA; [cited 2023 Apr 27]. Available from: https://www.ncqa.org/hedis/reports-and-research/national-collaborative-for-innovation-in-quality-measurement/hedis-measures-for-the-safe-judicious-use-of-antipsychotic-medications-in-children-and-adolescents/
    Google Scholar

  • 22 Department of Health and Human Services. 2015 annual report on the quality of care for children in Medicaid and CHIP [Internet]. Washington (DC): HHS; 2016 Feb [cited 2023 Jun 14]. Available from: https://www.medicaid.gov/medicaid/quality-of-care/downloads/2015-child-sec-rept.pdf
    Google Scholar

  • 23 Akincigil A, Mackie TI, Cook S, Hilt RJ, Crystal S. Effectiveness of mandatory peer review to reduce antipsychotic prescriptions for Medicaid-insured children. Health Serv Res. 2020;55(4):596–603. Crossref, MedlineGoogle Scholar
  • 24 Mackie TI, Cook S, Crystal S, Olfson M, Akincigil A. Antipsychotic use among youth in foster care enrolled in a specialized managed care organization intervention. J Am Acad Child Adolesc Psychiatry. 2020;59(1):166–176.e3. Crossref, MedlineGoogle Scholar
  • 25 Finnerty M, Neese-Todd S, Bilder S, Olfson M, Crystal S. Best practices: MEDNET: a multistate policy maker–researcher collaboration to improve prescribing practices. Psychiatr Serv. 2014;65(11):1297–9. Crossref, MedlineGoogle Scholar
  • 26 Findling RL, Drury SS, Jensen PS, Rapoport JL, Bukstein OG, Walter HJet al. Practice parameter for the use of atypical antipsychotic medications in children and adolescents [Internet]. Washington (DC): American Academy of Child and Adolescent Psychiatry; c 2011 [cited 2023 Apr 27]. Available from: https://www.aacap.org/App_Themes/AACAP/docs/practice_parameters/Atypical_Antipsychotic_Medications_Web.pdf
    Google Scholar

  • 27 Scotto Rosato N, Correll CU, Pappadopulos E, Chait A, Crystal S, Jensen PSet al. Treatment of maladaptive aggression in youth: CERT guidelines II. Treatments and ongoing management. Pediatrics. 2012;129(6):e1577–86. Crossref, MedlineGoogle Scholar
  • 28 Penfold RB, Thompson EE, Hilt RJ, Kelleher KJ, Schwartz N, Beck Aet al. Safer Use of Antipsychotics in Youth (SUAY) pragmatic trial protocol. Contemp Clin Trials. 2020;99:106184. Crossref, MedlineGoogle Scholar
  • 29 Stroup TS, Gerhard T, Crystal S, Huang C, Olfson M. Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia. Am J Psychiatry. 2016;173(2):166–73. Crossref, MedlineGoogle Scholar
  • 30 Olfson M, Gerhard T, Huang C, Lieberman JA, Bobo WV, Crystal S. Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia. Schizophr Bull. 2012;38(4):845–53. Crossref, MedlineGoogle Scholar
  • 31 National Institute for Health and Care Excellence. Psychosis and schizophrenia in children and young people: recognition and management [Internet]. London: NICE; 2013 Jan 23 [last updated 2016 Oct 26; cited 2023 Apr 27]. Available from: https://www.nice.org.uk/guidance/cg155
    Google Scholar

  • 32 Morrison AP, Pyle M, Maughan D, Johns L, Freeman D, Broome MRet al. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study. Lancet Psychiatry. 2020;7(9):788–800. Crossref, MedlineGoogle Scholar
  • 33 Cook BL, Carson NJ, Kafali EN, Valentine A, Rueda JD, Coe-Odess Set al. Examining psychotropic medication use among youth in the U.S. by race/ethnicity and psychological impairment. Gen Hosp Psychiatry. 2017;45:32–9. Crossref, MedlineGoogle Scholar
  • 34 Heun-Johnson H, Menchine M, Axeen S, Lung K, Claudius I, Wright Tet al. Association between race/ethnicity and disparities in health care use before first-episode psychosis among privately insured young patients. JAMA Psychiatry. 2021;78(3):311–9. Crossref, MedlineGoogle Scholar
  • 35 Corbie-Smith G, Thomas SB, St George DM. Distrust, race, and research. Arch Intern Med. 2002;162(21):2458–63. Crossref, MedlineGoogle Scholar
  • 36 DeLuca JS, Novacek DM, Adery LH, Herrera SN, Landa Y, Corcoran CMet al. Equity in mental health services for youth at clinical high risk for psychosis: considering marginalized identities and stressors. Evid Based Pract Child Adolesc Ment Health. 2022;7(2):176–97. Crossref, MedlineGoogle Scholar
  • 37 Vanderwerker L, Akincigil A, Olfson M, Gerhard T, Neese-Todd S, Crystal S. Foster care, externalizing disorders, and antipsychotic use among Medicaid-enrolled youths. Psychiatr Serv. 2014;65(10):1281–4. Crossref, MedlineGoogle Scholar
  • 38 Tan C, Greiner MV, Nause K, Shahabuddin Z, Beal SJ. Mental health diagnoses, health care utilization, and placement stability on antipsychotic prescribing among foster care youth. Acad Pediatr. 2023;23(3):675–80. Crossref, MedlineGoogle Scholar
  • 39 Dosreis S, Yoon Y, Rubin DM, Riddle MA, Noll E, Rothbard A. Antipsychotic treatment among youth in foster care. Pediatrics. 2011;128(6):e1459–66. Crossref, MedlineGoogle Scholar
  • 40 Leckman-Westin E, Finnerty M, Scholle SH, Pritam R, Layman D, Kealey Eet al. Differences in Medicaid antipsychotic medication measures among children with SSI, foster care, and income-based aid. J Manag Care Spec Pharm. 2018;24(3):238–46. Crossref, MedlineGoogle Scholar
  • 41 Lohr WD, Jawad K, Feygin Y, Le J, Creel L, Pasquenza Net al. Antipsychotic medications for low-income preschoolers: long duration and psychotropic medication polypharmacy. Psychiatr Serv. 2022;73(5):510–7. Crossref, MedlineGoogle Scholar
  • 42 Olfson M, King M, Schoenbaum M. Treatment of young people with antipsychotic medications in the United States. JAMA Psychiatry. 2015;72(9):867–74. Google Scholar
  • 43 Patel H, Barnes J, Osazuwa-Peters N, Bierut LJ. Association of state Medicaid expansion status with rates of suicide among US adults. JAMA Netw Open. 2022;5(6):e2217228. Crossref, MedlineGoogle Scholar
  • 44 Sommers BD, Blendon RJ, Orav EJ, Epstein AM. Changes in utilization and health among low-income adults after Medicaid expansion or expanded private insurance. JAMA Intern Med. 2016;176(10):1501–9. Crossref, MedlineGoogle Scholar